SCHEDULE: Armistice Capital Boosts Travere Therapeutics Stake to 7.52%
Beneficial Ownership Report
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 7.52% in Travere Therapeutics, Inc., holding 6,724,000 shares of common stock.
Summary
- Armistice Capital, LLC and Steven Boyd collectively hold 6,724,000 shares of Travere Therapeutics, Inc. common stock.
- This represents 7.52% of the company's outstanding common stock.
- The percentage is based on 89,472,327 shares outstanding as of October 27, 2025, as reported on the Issuer's Form 10-Q filed on October 30, 2025.
- Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd., exercises shared voting and investment power over these securities.
- Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 7
Explanation: The filing indicates a significant and continued beneficial ownership stake by a prominent investment firm, Armistice Capital, in Travere Therapeutics. While a 13G is a passive filing, maintaining or increasing such a stake can be interpreted as a positive signal of investor confidence, even if not explicitly stated for control purposes. The 'Amendment No. 7' suggests a history of involvement.
Positives
- A significant institutional investor, Armistice Capital, maintains a substantial stake (7.52%) in Travere Therapeutics, indicating continued interest or confidence in the company.
Negatives
- No specific negative information about Travere Therapeutics is disclosed in this beneficial ownership report.
Risks
- The concentration of a significant portion of voting and dispositive power (7.52%) in a single investment manager (Armistice Capital, LLC) and its managing member (Steven Boyd) could potentially influence corporate decisions, despite the stated intent not to change or influence control.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding Travere Therapeutics, Inc.'s future performance or operations.
Industry Context
This Schedule 13G filing indicates a significant passive investment by Armistice Capital, an institutional investor, in Travere Therapeutics. Such filings are common in the biotechnology and pharmaceutical sectors, where institutional holdings can signal investor interest in a company's pipeline or market position, without necessarily implying an intent to influence management control.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Beneficial Ownership Disclosure | Armistice Capital, LLC and Steven Boyd certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11. | 2025-09-30 | This certification indicates a passive investment stance, limiting direct governance impact beyond potential proxy voting or nomination activities under specific rules. |
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional holder may provide a degree of confidence or stability, as a large investor has a vested interest in the company's performance.
- Management: Management will be aware of a significant shareholder, which could subtly influence strategic decisions, though the filing states no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 2025-09-30 | Date of event which requires filing of this statement. |
| 2025-10-27 | Date as of which 89,472,327 shares outstanding were reported on the Issuer's Form 10-Q. |
| 2025-10-30 | Date the Issuer's Form 10-Q, reporting shares outstanding, was filed with the SEC. |
| 2025-11-14 | Date of signing and filing of this Schedule 13G Amendment No. 7. |
Keywords
Travere Therapeutics, Armistice Capital, Steven Boyd, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.